Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with Type 2 diabetes (SUSTAIN 5)

被引：0
|
作者：
Rodbard, H. [1 ]
Lingvay, I. [2 ]
Reed, J. [3 ]
de la Rosa, R. [4 ]
Rose, L. [5 ]
Sugimoto, D. [6 ]
Araki, E. [7 ]
Chu, P-L [8 ]
Wijayasingh, N. [9 ]
Norwood, P. [10 ]
Subramanian, G. [9 ]
机构：
[1] Endocrine & Metab Consultants, Endocrinol & Metab, Rockville, MD USA
[2] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[3] Endocrine Res Solut Inc, Roswell, GA USA
[4] Four Rivers Clin Res, Paducah, KY USA
[5] Diabet Res Inst, Munster, Germany
[6] Cedar Crosse Res Ctr, Chicago, IL USA
[7] Kumamoto Univ, Dept Metab Med, Kumamoto, Japan
[8] Novo Nordisk Inc, Plainsboro, NJ USA
[9] Novo Nordisk AS, Soborg, Denmark
[10] Univ Calif San Francisco, Fresno, CA USA
来源：
DIABETIC MEDICINE | 2017年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P370
引用
收藏
页码：145 / 146
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5)
    Rodbard, H.
    Lingvay, I.
    Reed, J.
    de la Rosa, R.
    Rose, L.
    Sugimoto, D.
    Araki, E.
    Chus, P. -L.
    Wijayasingh, N.
    Norwood, P.
    [J]. DIABETOLOGIA, 2016, 59 : S364 - S365
  • [2] Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2)
    Ahren, B.
    Comas, L. Masmiquel
    Kumar, H.
    Sargin, M.
    Karsbol, J. Derving
    Jacobsen, S. Hald
    Chow, F.
    [J]. DIABETOLOGIA, 2016, 59 : S365 - S365
  • [3] Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with Type 2 diabetes (SUSTAIN 2)
    Ahren, B.
    Comas, L. M.
    Kumar, H.
    Sargin, M.
    Karsbol, J. D.
    Jacobsen, S. H.
    Chow, F.
    [J]. DIABETIC MEDICINE, 2017, 34 : 145 - 145
  • [4] Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in subjects with Type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S-I
    Tsoukas, G.
    Unger, J.
    Karsbol, J. D.
    Bain, S.
    [J]. DIABETIC MEDICINE, 2017, 34 : 145 - 145
  • [5] Efficacy and Safety of Once-Weekly Semaglutide vs. Sitagliptin as Add-on to Metformin and/or Thiazolidinediones after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 2)
    Ahren, Bo
    Comas, Luis Masmiquel
    Kumar, Harish
    Sargin, Mehmet
    Karsbol, Julie Derving
    Jacobsen, Sanja Hald
    Chow, Francis
    [J]. DIABETES, 2016, 65 : A48 - A48
  • [6] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
    Harashima, Shin-ichi
    Sorli, Christopher
    Tsoukas, George
    Unger, Jeffrey
    Karsbol, Julie Derving
    Hansen, Thomas
    Bain, Stephen
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S121 - S121
  • [7] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S. -I.
    Tsoukas, G.
    Unger, J.
    Karsbol, J. Derving
    Hansen, T.
    Bain, S.
    [J]. DIABETOLOGIA, 2016, 59 : S364 - S364
  • [8] Efficacy and safety of once-weekly semaglutide versus sitagliptin as add-on to metformin and/or thiazolidinediones in subjects with T2D (SUSTAIN 2)
    Chow, Francis
    Ahren, Bo
    Comas, Lluis Masmiquel
    Kumar, Harish
    Sargin, Mehmet
    Karsbol, Julie Derving
    Jacobsen, Sanja Hald
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S122 - S122
  • [9] Efficacy and Safety of Tirzepatide vs. Semaglutide Once-Weekly as Add-On Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2)
    Frias, Juan Pablo
    Davies, Melanie J.
    Rosenstock, Julio
    Perez Manghi, Federico C.
    Lando, Laura Fernandez
    Bergman, Brandon
    Liu, Bing
    Cui, Xuewei
    Brown, Katelyn
    [J]. DIABETES, 2021, 70
  • [10] Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3)
    Ahmann, Andrew J.
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Chang, Denise
    Aroda, Vanita R.
    [J]. DIABETES, 2016, 65 : A49 - A49
12345